Global report - January 14, 2026
AstraZeneca acquires Modella AI
AstraZeneca is acquiring its AI partner Modella AI to own and deploy multimodal AI foundation models in‑house across discovery and development.
Acquisition - January 13, 2026
Novartis buys radioligand peptide program from PepLib
Novartis agreed to pay USD 50 million in cash upfront (plus undisclosed milestones) for a peptide‑based radioligand oncology program from Zonsen PepLib Biotech.
Global report - January 13, 2026
AbbVie and RemeGen in USD 5.6 billion oncology agreement
AbbVie and RemeGen have signed the first deal of the J.P Morgan Healthcare Conference 2026, with the companies agreeing to an exclusive oncology licensing agreement.
Global report - January 13, 2026
Eli Lilly and Nvidia commit USD 1 billion to AI co‑innovation lab
At the 2026 JPM Conference, Lilly and Nvidia announced an expanded AI partnership, including a USD 1 billion co‑innovation lab in the Bay Area to integrate advanced computing and biology for drug discovery.
Global report - December 9, 2025
Pfizer enters into agreement with YaoPharma
Pfizer has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical for the development, manufacturing and commercialization of YP05002, a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist currently in Phase 1 development for chronic weight management.
Global report - November 24, 2025
AstraZeneca plans USD 2 billion manufacturing investment in Maryland
This is the fourth major US manufacturing investment announced this year.
